STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Chan, Szeman R ^a   Vermi, William ^b   Luo, Jingqin ^a   Lucini, Laura ^b   Rickert, Charles ^a   Fowler, Amy M ^c   Lonardi, Silvia ^b   Arthur, Cora ^a   Young, Larry J T ^d   Levy, David E ^e   Welch, Michael J ^c   Cardiff, Robert D ^d   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; AREG PROTEIN; CD24 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN MYB; PROTEIN P63; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR B; RAG2 PROTEIN, MOUSE; STAT1 PROTEIN, HUMAN; STAT1 PROTEIN, MOUSE; TRANSCRIPTOME; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INFILTRATION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE CELL ANALYSIS; TUMOR BIOPSY; TUMOR ENGRAFTMENT; TUMOR SUPPRESSOR GENE; WILD TYPE; 129 MOUSE; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; C57BL MOUSE; CELL TRANSFORMATION; CLUSTER ANALYSIS; DNA MICROARRAY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MAMMARY GLAND; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; DOWN-REGULATION; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856010212     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3100     Document Type: Article

References (63)

1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002, 76:27-36. 10.1023/A:1020299707510, 12408373.
2. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001, 27:137-142. 10.1053/ctrv.2000.0207, 11417963.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
4. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 2010, 103:759-764. 10.1038/sj.bjc.6605845, 2966629, 20700118.
5. Simian M, Manzur T, Rodriguez V, de Kier Joffe EB, Klein S. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice. Breast Cancer Res Treat 2009, 113:1-8. 10.1007/s10549-007-9888-x, 18183485.
6. Kumar MJM, Ponvijay KS, Nandhini R, Nagarajan RS, Jose J, Srinivas G, Nagarajan P, Venkatesan R, Kumar K, Singh S. A mouse model for luminal epithelial like ER positive subtype of human breast cancer. BMC Cancer 2007, 7:180. 10.1186/1471-2407-7-180, 2094712, 17880731.
7. Efeyan A, Fabris V, Merani S, Lanari C, Molinolo AA. Establishment of two hormone-responsive mouse mammary carcinoma cell lines derived from a metastatic mammary tumor. Breast Cancer Res Treat 2004, 83:233-244. 10.1023/B:BREA.0000014044.02728.ac, 14758093.
8. Aidells BD, Daniel CW. Hormone-dependent mammary tumors in strain GR/A mice. III. Effectiveness of supplementary hormone treatments in inducing tumorous phase growth. J Natl Cancer Inst 1976, 57:527-537.
9. Bach EA, Aguet M, Schreiber RD. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997, 15:563-591. 10.1146/annurev.immunol.15.1.563, 9143700.
10. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442. 10.1016/S0092-8674(00)81288-X, 8608597.
11. Durbin JE, Hackenmiller R, Celeste Simon M, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450. 10.1016/S0092-8674(00)81289-1, 8608598.
12. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95:7556-7561. 10.1073/pnas.95.13.7556, 22681, 9636188.
13. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111. 10.1038/35074122, 11323675.
14. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848. 10.1038/nri1961, 17063185.
15. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997, 278:1630-1632. 10.1126/science.278.5343.1630, 9374464.
16. Wang S, Raven JF, Durbin JE, Koromilas AE. Stat1 phosphorylation determines Ras oncogenicity by regulating p27kip1. PLoS One 2008, 3:e4376.
17. Lee C-K, Smith E, Gimeno R, Gertner R, Levy DE. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-γ. J Immunol 2000, 164:1286-1292.
18. Ouchi F, Lee SW, Ouchi M, Aaronson SA, Horvath CM. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFNγ target genes. Proc Natl Acad Sci USA 2000, 97:5208-5213. 10.1073/pnas.080469697, 25807, 10792030.
19. Townsend PA, Cragg MS, Davidson SM, McCormick J, Barry S, Lawrence KM, Knight RA, Hubank M, Chen P-L, Latchman DS, Stephanou A. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci 2005, 118:1629-1639. 10.1242/jcs.01728, 15784679.
20. Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG, Harkin DP. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene 2005, 24:5492-5501. 10.1038/sj.onc.1208698, 15940267.
21. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011, 10:794-804. 10.4161/cc.10.5.14956, 21311224.
22. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 2010, 12:899-905. 2978912, 21076615.
23. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 2004, 101:1714-1719. 10.1073/pnas.0308102100, 341831, 14755057.
24. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007, 67:9214-9220. 10.1158/0008-5472.CAN-07-1019, 17909027.
25. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 2008, 105:18490-18495. 10.1073/pnas.0809242105, 2587578, 19001271.
26. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R, Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010, 29:920-929. 10.1038/onc.2009.391, 2820589, 19915608.
27. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
28. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, Alt FW. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68:855-867. 10.1016/0092-8674(92)90029-C, 1547487.
29. Ramsden DA, Gellert M. Formation and resolution of double-strand break intermediates in V(D)J rearrangement. Genes Dev 1995, 9:2409-2420. 10.1101/gad.9.19.2409, 7557392.
30. Kuhnel B, Buetti E, Diggelmann H. Functional analysis of the glucocorticoid regulatory elements present in the mouse mammary tumor virus long terminal repeat. J Mol Biol 1986, 190:367-378. 10.1016/0022-2836(86)90008-2, 3023640.
31. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006, 8:R7. 10.1186/bcr1371, 1413978, 16417656.
32. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88. 10.1038/nature04372, 16397499.
33. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
34. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36. 10.1073/pnas.011404098, 14539, 11134512.
35. Mouse Genome Informatics-Mammalian Orthology. , http://www.informatics.jax.org/orthology.shtml
36. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtzov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
37. Cancer Biomedical Informatics Grid, National Cancer Institute Distance-weighted discrimination. Cancer Biomedical Informatics Grid, National Cancer Institute., https://cabig.nci.nih.gov/tools/DWD
38. Marron JS, Todd MJ, Ahn J. Distance-Weighted Discrimination. Journal of American Statistical Association 2007, 102:1267-1271.
39. Shenkin PS, McDonald DQ. Cluster analysis of molecular conformations. J Comput Chem 1994, 15:899-916.
40. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248. 10.1093/bioinformatics/bth349, 15180930.
41. Gene Expression Omnibus. , http://www.ncbi.nlm.nih.gov/geo
42. Liu Y, Hayes DN, Nobel A, Marron JS. Statistical significance of clustering for high dimension low sample size data. J Am Stat Assoc 2008, 103:1281-1293.
43. Monti S, Tamayo P, Mesirov J, Golub TR. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 2003, 52:91-118.
44. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH. A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 1981, 37:383-390. 10.2307/2530427, 7272422.
45. The Comprehensive R Archive Network: R 2.11.1. , http://cran.r-project.org
46. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JCF, Lashkari D, Shalon D, Brown PO, Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96:9212-9217. 10.1073/pnas.96.16.9212, 17759, 10430922.
47. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009, 124:2124-2134. 10.1002/ijc.24177, 19142869.
48. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. Biologic consequences of STAT1-independent IFN signaling. Proc Natl Acad Sci USA 2001, 98:6680-6685. 10.1073/pnas.111163898, 34412, 11390995.
49. Wang D, Coscoy L, Zylberberg M, Avila PC, Boushey HA, Ganem D, DeRisi JL. Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci USA 2002, 99:15687-15692. 10.1073/pnas.242579699, 137777, 12429852.
50. Cardiff RD, Anver MR, Boivin GP, Bosenberg MW, Maronpot RR, Molinolo AA, Nikitin AY, Rehg JE, Thomas GV, Russell RG, Ward JM. Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol 2006, 34:699-707. 10.1080/01926230600930129, 17074738.
51. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 2005, 8:R6. 1413990, 16417654.
52. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001, 30:67-71.
53. Levy DE, Darnell JE. STATs: Transcriptional control and biological impact. Rev Cell Biol 2002, 3:651-662.
54. Presneau N, Manderson EN, Tonin PN. The quest for a tumor suppressor gene phenotype. Curr Mol Med 2003, 3:605-629. 10.2174/1566524033479500, 14601636.
55. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M, Decker T. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFNγ-dependent innate immunity. Immunity 2003, 19:793-802. 10.1016/S1074-7613(03)00322-4, 14670297.
56. Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst 2006, 98:181-189. 10.1093/jnci/djj020, 16449678.
57. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 9:33-45.
58. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006, 98:1011-1014. 10.1093/jnci/djj267, 16849684.
59. Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. Embo J 1998, 17:3660-3668. 10.1093/emboj/17.13.3660, 1170702, 9649436.
60. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Muller M, Decker T. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. Embo J 2001, 20:91-100. 10.1093/emboj/20.1.91, 140204, 11226159.
61. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. EBCTCG.
62. Harichand-Herdt S, Zelnak A, O'Regan R. Endocrine therapy for the treatment of postmenopausal women with breast cancer. Expert Rev Anticancer Ther 2009, 9:187-198. 10.1586/14737140.9.2.187, 19192957.
63. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. 3163848, 21802721.